Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.